Therapeutic | Dalotuzumab |
Target | IGF1R |
Heavy Chain | QVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSS |
Light Chain | DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2009 |
INN Year Recommended | 2010 |
Companies Involved | Pierre Fabre, Merck & Co |
Conditions Approved | na |
Conditions Active | Breast cancer, Colorectal cancer, Pancreatic cancer |
Conditions Discontinued | Multiple myeloma, Neuroendocrine tumours, Non-small cell lung cancer, Solid tumours |
Notes | Jain paper: "Entries in WHO-INN documents (PL102 and RL64) have errors" |